HomeCompareAURQF vs PFE

AURQF vs PFE: Dividend Comparison 2026

AURQF yields 133333.33% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AURQF wins by $8.549287649225948e+27M in total portfolio value
10 years
AURQF
AURQF
● Live price
133333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.549287649225948e+27M
Annual income
$8,536,692,923,921,903,000,000,000,000,000,000.00
Full AURQF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AURQF vs PFE

📍 AURQF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAURQFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AURQF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AURQF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AURQF
Annual income on $10K today (after 15% tax)
$11,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,256,188,985,333,618,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AURQF beats the other by $7,256,188,985,333,618,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AURQF + PFE for your $10,000?

AURQF: 50%PFE: 50%
100% PFE50/50100% AURQF
Portfolio after 10yr
$4.274643824612974e+27M
Annual income
$4,268,346,461,960,951,400,000,000,000,000,000.00/yr
Blended yield
99.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AURQF
No analyst data
Altman Z
-11.5
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AURQF buys
0
PFE buys
0
No recent congressional trades found for AURQF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAURQFPFE
Forward yield133333.33%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$8.549287649225948e+27M$49.6K
Annual income after 10y$8,536,692,923,921,903,000,000,000,000,000,000.00$26,258.71
Total dividends collected$8.548462633639563e+27M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AURQF vs PFE ($10,000, DRIP)

YearAURQF PortfolioAURQF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$13,344,033$13,333,333.33$9,153$693.39+$13.33MAURQF
2$16,642,357,036$16,628,078,920.04$8,593$849.25+$16642.35MAURQF
3$19,399,246,208,345$19,381,438,886,316.95$8,336$1,066.78+$19399246.20MAURQF
4$21,134,841,850,983,004$21,114,084,657,540,070.00$8,437$1,384.80+$21134841850.97MAURQF
5$21,520,840,488,109,330,000$21,498,226,207,328,780,000.00$9,013$1,875.40+$21520840488109.32MAURQF
6$20,481,776,417,848,300,000,000$20,458,749,118,526,020,000,000.00$10,306$2,680.72+$20481776417848300.00MAURQF
7$18,219,078,762,075,947,000,000,000$18,197,163,261,308,848,000,000,000.00$12,820$4,101.38+$18219078762075947008.00MAURQF
8$15,147,396,542,885,863,000,000,000,000$15,127,902,128,610,440,000,000,000,000.00$17,673$6,826.70+$1.5147396542885863e+22MAURQF
9$11,770,771,312,189,630,000,000,000,000,000$11,754,563,597,888,743,000,000,000,000,000.00$27,543$12,591.86+$1.1770771312189631e+25MAURQF
10$8,549,287,649,225,948,000,000,000,000,000,000$8,536,692,923,921,903,000,000,000,000,000,000.00$49,560$26,258.71+$8.549287649225948e+27MAURQF

AURQF vs PFE: Complete Analysis 2026

AURQFStock

Aurelius Minerals Inc., an exploration stage company, engages in acquisition, exploration, and evaluation of mineral properties in Canada. The company explores for gold. It holds a 100% interest in the Lipton property with 57 claims covering an area of approximately 12,425 hectares; and the Mikwam property with 69 cell claims covering an area of approximately 968 hectares located within the northern Abitibi Gold Belt in Ontario. The company also holds interests in the Aureus gold properties, including Aureus West and East with 104 mineral claims covering an area of approximately 1,684 hectares in Abitibi Greenstone Belt in Ontario; the Tangier gold project; and the Forest Hill Gold project comprise 115 contiguous mineral exploration claims in four exploration licenses with an aggregate area of 1,840 hectares. The company was formerly known as Galena International Resources Ltd. and changed its name to Aurelius Minerals Inc. in January 2017. Aurelius Minerals Inc. was incorporated in 2007 and is based in Toronto, Canada.

Full AURQF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AURQF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AURQF vs SCHDAURQF vs JEPIAURQF vs OAURQF vs KOAURQF vs MAINAURQF vs JNJAURQF vs MRKAURQF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.